RT Journal Article
SR Electronic
T1 Isolevuglandins promote autoimmunity and hypertension in systemic lupus erythematosus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.10.20021741
DO 10.1101/2020.02.10.20021741
A1 Patrick, David M.
A1 de la Visitación, Nestor
A1 Ormseth, Michelle J.
A1 Stein, C. Michael
A1 Davies, Sean S.
A1 Yermalitksy, Valery N.
A1 Amarnath, Venkataraman
A1 Crofford, Leslie J.
A1 Williams, Jonathan M.
A1 Dikalov, Sergey
A1 Dikalova, Anna
A1 Xiao, Liang
A1 Van Beusecum, Justin P.
A1 Ao, Mingfang
A1 Fogo, Agnes B.
A1 Kirabo, Annet
A1 Harrison, David G.
YR 2020
UL http://medrxiv.org/content/early/2020/02/12/2020.02.10.20021741.abstract
AB Hypertension, vascular inflammation and renal inflammation are characteristic of systemic lupus erythematosus (SLE), a multisystem autoimmune disease that is complex and poorly understood. Oxidation products of arachidonic and other fatty acids, termed isolevuglandins (isoLG) lead to formation of post-translational protein modifications that are immunogenic. We demonstrate isoLG enrichment in dendritic cells (DCs), B cells, and plasma cells from juvenile female B6.SLE123 mice. In adult B6.SLE123 and NZBWF1 mice, isoLG adducts are enriched in plasma cells and splenic DCs compared to C57Bl/6 and NZW mice respectively. Treatment with the isoLG-scavenger 2-hydroxybenzylamine (2-HOBA) reduced blood pressure, improved renal function, and attenuated renal injury. Moreover, 2-HOBA reduced bone marrow plasma cells, total IgG levels, and anti-dsDNA antibody titers. We also demonstrate that mice with SLE generate specific IgG antibodies against isoLG adducted protein, confirming the immunogenicity of isoLG adducts. Finally, we found that isoLG adducted peptides are markedly enriched in monocytes from patients with SLE which was accompanied by an increase in superoxide production. These findings support a role of isoLG adducts in the genesis and maintenance of systemic autoimmunity and its associated hypertension in SLE. Scavenging of isoLGs promises to be a novel therapy for this disease.Competing Interest StatementDavid Patrick and David Harrison have a patent pending to use 2-HOBA to treat SLE.Funding StatementThis work is supported by National Institute of Health grants 5R35HL140016-02, 5P01HL129941-03, 1R01HL134895-02. Dr. Patrick was funded by the T32 GM007569-44 and is the recipient of a National Institute of Health Ruth L. Kirschstein Individual National Research Service Award (F32HL144050).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will make all data available upon reasonable request.